PE20211465A1 - Inhibidores de la proteina tirosina fosfatasa - Google Patents
Inhibidores de la proteina tirosina fosfatasaInfo
- Publication number
- PE20211465A1 PE20211465A1 PE2021000527A PE2021000527A PE20211465A1 PE 20211465 A1 PE20211465 A1 PE 20211465A1 PE 2021000527 A PE2021000527 A PE 2021000527A PE 2021000527 A PE2021000527 A PE 2021000527A PE 20211465 A1 PE20211465 A1 PE 20211465A1
- Authority
- PE
- Peru
- Prior art keywords
- hydrogen
- alkyl
- halogen
- optionally substituted
- protein tyrosine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se proporcionan compuestos de la Formula Ia, donde: X1 es CH o N; X2 es CH o N; X3 es CH o N; L1 es un enlace directo, S, CH2, O o NH; R1 es fenilo, heteroarilo, arilo biciclico, heterociclilo biciclico y biciclico heteroarilo, todos ellos opcionalmente sustituidos con halogeno, OH, oxo, ciano, entre otros; R2 es (A); X11 es CR13R14, SiR13R14, NH u O; X12 es CHR15 o NH, en donde uno o ambos de X11 y X12 debe ser carbono; R10 es hidrogeno o alquilo; R11 es hidrogeno, OH o CH2NH2; R12, R16 y R17 son hidrogeno; R13 es hidrogeno, OH o (alquilo C0-C3)NRbRc; R14 es hidrogeno, OH, alquilo opcionalmente sustituido con halogeno, OH, metilo, OCH3 o un heteroarilo; R15 es hidrogeno o NH2; R48 es hidrogeno o metilo; Ra es hidrogeno, alquilo opcionalmente sustituido con OH, metoxi, halogeno o ciano o ciclopropilo; Rb y Rc son hidrogeno, alquilo o un grupo Boc; y a, b, c y d se seleccionan de 0 y 1. Dichos compuestos inhiben la proteina tirosina fosfatasa y son utiles para el tratamiento de enfermedades hiperproliferativas y neopasicas.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862746952P | 2018-10-17 | 2018-10-17 | |
| US201962916119P | 2019-10-16 | 2019-10-16 | |
| PCT/US2019/056786 WO2020081848A1 (en) | 2018-10-17 | 2019-10-17 | Protein tyrosine phosphatase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211465A1 true PE20211465A1 (es) | 2021-08-05 |
Family
ID=68536896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021000527A PE20211465A1 (es) | 2018-10-17 | 2019-10-17 | Inhibidores de la proteina tirosina fosfatasa |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20210380582A1 (es) |
| EP (1) | EP3867238B1 (es) |
| JP (1) | JP7449282B2 (es) |
| KR (1) | KR102649419B1 (es) |
| CN (1) | CN114341124A (es) |
| AU (1) | AU2019359885B2 (es) |
| BR (1) | BR112021005733A2 (es) |
| CA (1) | CA3116561C (es) |
| CL (1) | CL2021000972A1 (es) |
| CO (1) | CO2021004966A2 (es) |
| CR (1) | CR20210189A (es) |
| CU (1) | CU20210029A7 (es) |
| CY (1) | CY1126122T1 (es) |
| DO (1) | DOP2021000070A (es) |
| EC (1) | ECSP21027049A (es) |
| ES (1) | ES2947464T3 (es) |
| HU (1) | HUE062404T2 (es) |
| IL (1) | IL282179A (es) |
| MA (1) | MA53921A (es) |
| MX (1) | MX2021004410A (es) |
| NI (1) | NI202100027A (es) |
| PE (1) | PE20211465A1 (es) |
| PH (1) | PH12021550674A1 (es) |
| PL (1) | PL3867238T3 (es) |
| SG (1) | SG11202102985YA (es) |
| WO (1) | WO2020081848A1 (es) |
| ZA (1) | ZA202101960B (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3515916B1 (en) | 2016-09-22 | 2023-06-07 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
| TW201819386A (zh) | 2016-10-24 | 2018-06-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
| EP3630770A1 (en) | 2017-05-26 | 2020-04-08 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
| US11701354B2 (en) | 2017-09-29 | 2023-07-18 | D. E. Shaw Research, Llc | Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors |
| TW202003471A (zh) | 2018-03-21 | 2020-01-16 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
| WO2020072656A1 (en) | 2018-10-03 | 2020-04-09 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
| GEP20237561B (en) | 2019-04-02 | 2023-10-25 | Array Biopharma Inc | Protein tyrosine phosphatase inhibitors |
| EP4034539A1 (en) | 2019-09-24 | 2022-08-03 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of making and using the same |
| CN114901662A (zh) | 2019-11-08 | 2022-08-12 | 锐新医药公司 | 双环杂芳基化合物及其用途 |
| IL299131A (en) | 2020-06-18 | 2023-02-01 | Revolution Medicines Inc | Methods for delaying, preventing and treating acquired resistance to RAS inhibitors |
| EP4208261A1 (en) | 2020-09-03 | 2023-07-12 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| EP4214209A1 (en) | 2020-09-15 | 2023-07-26 | Revolution Medicines, Inc. | Indole derivatives as ras inhibitors in the treatment of cancer |
| TWI825637B (zh) | 2021-03-31 | 2023-12-11 | 美商輝瑞股份有限公司 | 啶－１，６（２ｈ，７ｈ）－二酮 |
| EP4334321A1 (en) | 2021-05-05 | 2024-03-13 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| CN117616031A (zh) | 2021-05-05 | 2024-02-27 | 锐新医药公司 | 用于治疗癌症的ras抑制剂 |
| CN115960109A (zh) * | 2021-05-31 | 2023-04-14 | 药雅科技(上海)有限公司 | 稠环类shp2磷酸酶抑制剂的制备及其应用 |
| CN115340561A (zh) * | 2021-05-14 | 2022-11-15 | 药雅科技(上海)有限公司 | Shp2磷酸酶稠环类抑制剂的制备及其应用 |
| TW202244049A (zh) * | 2021-05-12 | 2022-11-16 | 大陸商藥雅科技（上海）有限公司 | Shp2磷酸酶抑制劑的製備及其應用 |
| WO2022259157A1 (en) | 2021-06-09 | 2022-12-15 | Novartis Ag | A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor |
| TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途 |
| KR20230011245A (ko) | 2021-07-09 | 2023-01-20 | 주식회사 카나프테라퓨틱스 | Shp2 억제제 및 이의 용도 |
| KR20240055778A (ko) | 2021-09-01 | 2024-04-29 | 노파르티스 아게 | Tead 억제제를 포함하는 제약 조합물 및 암의 치료를 위한 이의 용도 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| TW202346305A (zh) * | 2022-01-05 | 2023-12-01 | 美商雷密克斯醫療公司 | 用於調節剪切之化合物及方法 |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| CN114621186A (zh) * | 2022-05-12 | 2022-06-14 | 上海维申医药有限公司 | 作为ras信号通路调控剂的杂环化合物 |
| WO2023230205A1 (en) | 2022-05-25 | 2023-11-30 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| JPWO2007029847A1 (ja) * | 2005-09-07 | 2009-03-19 | 萬有製薬株式会社 | 二環性芳香族置換ピリドン誘導体 |
| US9481675B2 (en) * | 2009-09-11 | 2016-11-01 | Merck Sharp & Dohme Corp. | Gyrase inhibitors |
| CA2804304C (en) * | 2010-05-24 | 2020-02-25 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| US9815813B2 (en) | 2014-01-17 | 2017-11-14 | Novartis Ag | 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2 |
| ES2699351T3 (es) | 2014-01-17 | 2019-02-08 | Novartis Ag | Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2 |
| CN112625028A (zh) | 2015-06-19 | 2021-04-09 | 诺华股份有限公司 | 用于抑制shp2活性的化合物和组合物 |
| EP3310771B1 (en) | 2015-06-19 | 2020-07-22 | Novartis AG | Compounds and compositions for inhibiting the activity of shp2 |
| ES2741746T3 (es) | 2015-06-19 | 2020-02-12 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de SHP2 |
| WO2017210134A1 (en) | 2016-05-31 | 2017-12-07 | Board Of Regents, University Of Texas System | Heterocyclic inhibitors of ptpn11 |
| CA3026784A1 (en) | 2016-06-07 | 2017-12-14 | Jacobio Pharmaceuticals Co., Ltd. | Heterocyclic pyrazine derivatives useful as shp2 inhibitors |
| MX2018015625A (es) | 2016-06-14 | 2019-03-06 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de shp2. |
| SG11201900157RA (en) | 2016-07-12 | 2019-02-27 | Revolution Medicines Inc | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
| EP3515916B1 (en) | 2016-09-22 | 2023-06-07 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
| TW201819386A (zh) * | 2016-10-24 | 2018-06-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
| EP3571189B1 (en) | 2017-01-23 | 2023-03-29 | Revolution Medicines, Inc. | Pyridine compounds as allosteric shp2 inhibitors |
| JP7240319B2 (ja) | 2017-01-23 | 2023-03-15 | レヴォリューション・メディスンズ，インコーポレイテッド | アロステリックｓｈｐ２阻害剤としての二環式化合物 |
| EP3601239A4 (en) | 2017-03-23 | 2020-05-13 | Jacobio Pharmaceuticals Co., Ltd. | INNOVATIVE HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS |
| WO2019051084A1 (en) | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | SHP2 INHIBITOR COMPOSITIONS AND METHODS OF TREATING CANCER |
-
2019
- 2019-10-17 BR BR112021005733-1A patent/BR112021005733A2/pt unknown
- 2019-10-17 HU HUE19801996A patent/HUE062404T2/hu unknown
- 2019-10-17 CR CR20210189A patent/CR20210189A/es unknown
- 2019-10-17 JP JP2021520556A patent/JP7449282B2/ja active Active
- 2019-10-17 MX MX2021004410A patent/MX2021004410A/es unknown
- 2019-10-17 CU CU2021000029A patent/CU20210029A7/es unknown
- 2019-10-17 US US17/285,997 patent/US20210380582A1/en active Pending
- 2019-10-17 WO PCT/US2019/056786 patent/WO2020081848A1/en active Application Filing
- 2019-10-17 KR KR1020217014574A patent/KR102649419B1/ko active IP Right Grant
- 2019-10-17 SG SG11202102985YA patent/SG11202102985YA/en unknown
- 2019-10-17 AU AU2019359885A patent/AU2019359885B2/en active Active
- 2019-10-17 EP EP19801996.0A patent/EP3867238B1/en active Active
- 2019-10-17 PE PE2021000527A patent/PE20211465A1/es unknown
- 2019-10-17 ES ES19801996T patent/ES2947464T3/es active Active
- 2019-10-17 CA CA3116561A patent/CA3116561C/en active Active
- 2019-10-17 MA MA053921A patent/MA53921A/fr unknown
- 2019-10-17 PL PL19801996.0T patent/PL3867238T3/pl unknown
- 2019-10-17 CN CN201980068343.2A patent/CN114341124A/zh active Pending
-
2021
- 2021-03-24 ZA ZA2021/01960A patent/ZA202101960B/en unknown
- 2021-03-25 PH PH12021550674A patent/PH12021550674A1/en unknown
- 2021-04-08 IL IL282179A patent/IL282179A/en unknown
- 2021-04-16 NI NI202100027A patent/NI202100027A/es unknown
- 2021-04-16 CL CL2021000972A patent/CL2021000972A1/es unknown
- 2021-04-16 EC ECSENADI202127049A patent/ECSP21027049A/es unknown
- 2021-04-16 DO DO2021000070A patent/DOP2021000070A/es unknown
- 2021-04-19 CO CONC2021/0004966A patent/CO2021004966A2/es unknown
-
2023
- 2023-08-01 CY CY20231100379T patent/CY1126122T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2021000972A1 (es) | 2021-10-15 |
| CU20210029A7 (es) | 2021-11-04 |
| NI202100027A (es) | 2021-08-24 |
| PL3867238T3 (pl) | 2023-09-11 |
| SG11202102985YA (en) | 2021-05-28 |
| MX2021004410A (es) | 2021-07-06 |
| AU2019359885A1 (en) | 2021-04-15 |
| DOP2021000070A (es) | 2021-05-16 |
| ZA202101960B (en) | 2023-11-29 |
| US20210380582A1 (en) | 2021-12-09 |
| EP3867238C0 (en) | 2023-06-07 |
| KR20210076098A (ko) | 2021-06-23 |
| JP7449282B2 (ja) | 2024-03-13 |
| CN114341124A (zh) | 2022-04-12 |
| ECSP21027049A (es) | 2021-05-31 |
| WO2020081848A1 (en) | 2020-04-23 |
| AU2019359885B2 (en) | 2024-01-18 |
| EP3867238B1 (en) | 2023-06-07 |
| KR102649419B1 (ko) | 2024-03-21 |
| IL282179A (en) | 2021-05-31 |
| CR20210189A (es) | 2021-09-14 |
| BR112021005733A2 (pt) | 2021-07-27 |
| PH12021550674A1 (en) | 2021-12-13 |
| MA53921A (fr) | 2022-01-26 |
| CA3116561A1 (en) | 2020-04-23 |
| HUE062404T2 (hu) | 2023-10-28 |
| CA3116561C (en) | 2023-09-12 |
| CO2021004966A2 (es) | 2021-04-30 |
| EP3867238A1 (en) | 2021-08-25 |
| ES2947464T3 (es) | 2023-08-09 |
| JP2022504936A (ja) | 2022-01-13 |
| CY1126122T1 (el) | 2023-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20211465A1 (es) | Inhibidores de la proteina tirosina fosfatasa | |
| PE20211411A1 (es) | Compuestos de anillo fusionado | |
| PE20170189A1 (es) | Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1 | |
| PE20190509A1 (es) | 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas | |
| PE20091371A1 (es) | Inhibidores de hsp90 | |
| PE20170143A1 (es) | Benzimidazol-2-aminas como inhibidores de midh1 | |
| UY37362A (es) | Sulfonilureas y compuestos relacionados y sus usos | |
| PE20070752A1 (es) | Triazolopiridazinas como moduladores de quinasa | |
| AR073079A1 (es) | Compuestos triazolopiridina como inhibidores de pim cinasa | |
| PE20141597A1 (es) | Triazolopiridinas sustituidas | |
| PE20171177A1 (es) | Compuestos aminopirimidinilo inhibidores de jak | |
| PE20171329A1 (es) | Agentes inmunorreguladores | |
| PE20141974A1 (es) | Compuestos de heterociclilo | |
| PE20150767A1 (es) | Inhibidores de gdf-8 | |
| PE20090370A1 (es) | Derivados de heterociclo fusionado como inhibidores de quinasa | |
| MX2011011875A (es) | Compuesto de carboxamida heterociclica diamino. | |
| PE20121282A1 (es) | Antagonistas de espiro-oxindol de mdm2 | |
| PE20190111A1 (es) | Nuevos derivados aminoacido, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| AR053778A1 (es) | Compuestos de quinazolina para el tratamiento de desordenes mediados por la proteina quinasa | |
| PE20091408A1 (es) | Compuestos y composiciones como inhibidores de cinasa | |
| PE20081534A1 (es) | Piperidinas sustituidas que tienen actividad inhibidoras de la proteina cinasa | |
| AR053120A1 (es) | Aminopiridinas como inhibidores de beta secretasa | |
| PE20121327A1 (es) | Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello | |
| PE20161444A1 (es) | 1,2-ciclopentanos sustituidos como antagonistas del receptor de orexina | |
| EA201290073A1 (ru) | Соединения мочевины, содержащие 5,6-бициклический гетероарил, как ингибиторы киназ |